Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Cancer broadly; engineered cytokine-antibody fusion for targeted expansion of immune effector cells via IL-2 pathway
Modality
Monoclonal Antibody
Mechanism
IL-2 cytokine-antibody fusion
Target
IL-2
rNPV Envelope
Low
-$67.0M
costs +25% · peak −25%
Base
-$49.9M
cumulative PoS 2.0%
High
-$32.7M
costs −25% · peak +25%
Costs follow oncology biologic/immunocytokine norms. PoS is below standard oncology biologics because the IL-2 engineering field is crowded and bempegaldesleukin's Phase 3 failures materially reduce confidence in CD122/effector-biased IL-2 translation.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.65
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.564 — composite-score rank #48 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#47) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Aldesleukin / Proleukin - high-dose IL-2
Foundational IL-2 therapy comparator: approved in metastatic melanoma and renal cell carcinoma but limited by severe toxicity, short half-life, and low durable-response rates.
Criteria 1 and 2: same IL-2 pathway and oncology use; toxicity/efficacy anchor.
Bempegaldesleukin / NKTR-214
Most important engineered IL-2 cautionary precedent. Despite promising Phase 2 data, the nivolumab combination failed Phase 3 in untreated advanced melanoma.
Criteria 1 and 3: same engineered IL-2 class; stale/cautionary only.
Simlukafusp alfa / FAP-IL2v
Closest immunocytokine-class comparator: an antibody-fused IL-2 variant designed to localize IL-2 activity in tumors and avoid CD25/Treg engagement.
Criteria 1 and 4: same immunocytokine class, different targeting antibody and clinical maturity.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $18.0M | 24 mo | 40.0% | [0] [1] |
| Phase I | $60.0M | 18 mo | 58.0% | [0] [1] [3] |
| Phase II | $160.0M | 30 mo | 24.0% | [1] [2] [3] |
| Phase III | $330.0M | 42 mo | 42.0% | [1] [2] |
| NDA/BLA Review | $16.0M | 12 mo | 84.0% | [1] |
Multiplier handling: Eligible multipliers (immune_effector_mechanism) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$450.0M peak · WACC 14.0%
Peak revenue. A safer, human IL-2/antibody fusion could be commercially meaningful in a selected solid-tumor combination niche, but the crowded engineered-IL-2 landscape and bempeg failure argue against blockbuster assumptions. The $450M peak assumes partnered development with checkpoint/vaccine combinations rather than broad IL-2 replacement.
WACC. Oncology biologic category is familiar, but cytokine safety and engineered-IL-2 class failure keep risk above standard mAbs.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$49.9M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$201.7M
P25
-$78.1M
P50 (median)
-$22.8M
P75
-$12.4M
P95
-$6.5M
Prob ≥ 0
1.0%
Evidence register
5 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is human IL-2/602 cytokine-antibody fusion cmo_findings.asset_class_reality | Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells regulatory | 2023-10-24 | high |
Aldesleukin approved IL-2 anchor comparators[0] | Aldesleukin - NCI drug information regulatory | 2025-01-01 | high |
High-dose IL-2 toxicity and short therapeutic window stage_profile.phase_1.pos | Interleukin-2 - Holland-Frei Cancer Medicine peer_review | 2003-01-01 | high |
Bempeg Phase 3 cautionary precedent comparators[1] | Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: PIVOT IO 001 Trial Results peer_review | 2023-09-01 | high |
Immunocytokine class comparator comparators[2] | Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy peer_review | 2021-05-07 | high |
Thesis
Why this asset earns its rank
This is a real therapeutic concept, but it is an engineered IL-2 immunocytokine, not a plain mAb. The JHU asset uses a human analog of the S4B6 antibody, 602, fused to human IL-2 to bias activity toward immune effector cells and away from Treg activation/free IL-2 toxicity. The pinned monoclonal_antibody bucket is therefore an approximation for an antibody-cytokine fusion.
The comparator frame is high-risk but real. Aldesleukin proves IL-2 can produce durable cancer responses but with severe toxicity and short half-life; bempegaldesleukin shows that engineered IL-2 biology can still fail Phase 3 despite promising early data; simlukafusp alfa anchors the antibody-fusion immunocytokine class. The engine result is -$67.0M to -$32.7M, with a base rNPV of -$49.9M and cumulative PoS of 2.0%; that supports a partner-first oncology-biologic path if the fusion shows differentiated effector bias and safety versus the crowded engineered-IL-2 field.
Verdict: credible but class-risk-heavy. It earns its rank through IL-2 pathway relevance, oncology breadth, and biologic modality strength, while the funding case depends on proving this specific IL-2/602 fusion solves the toxicity and efficacy problems that have hurt the field.
Key risks
Asset-specific, not generic biotech risks
- Modality mismatch: the asset is an IL-2 cytokine-antibody fusion, not a conventional antibody.
- Class failure risk: bempegaldesleukin's Phase 3 failures make any engineered IL-2 efficacy claim harder to defend.
- Safety risk: any dissociation, off-target IL-2 signaling, vascular leak, or Treg activation would undermine the core value proposition.
- Crowded field: multiple engineered IL-2 and immunocytokine programs compete for the same combination niches.